Business Wire

NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASCO Annual Meeting and Invitation to a Dedicated KOL Event

BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor ...
Business Wire

NOXXON Presents Full Top-line Results From NOX-A12 Phase 1/2 GLORIA Trial in Glioblastoma at the 2022 ASCO Annual Meeting

BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor ...
ascopubs.org

Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.

Prognostic value of hPG80 (circulating progastrin) in IDH-wild type glioblastoma treated with radio-chemotherapy. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...